Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (591-600 of 713) with videos related to

Pageof 72
Sort By:
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Blood|August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
Journal of Hematology & Oncology|January 5, 2019
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceKamal Chamoun, Hagop Kantarjian, Rami Atallah, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
American Journal of Hematology|January 5, 2017
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionNaveen Pemmaraju, Hagop Kantarjian, Jeffrey L Jorgensen, et al.
Blood|January 6, 2016
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsPreetesh Jain, Hagop Kantarjian, Keyur P Patel, et al.
Cancer|October 16, 2018
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential valueJuliana E Hidalgo-Lόpez, Rashmi Kanagal-Shamanna, Andrés E Quesada, et al.
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid LeukemiaXuejie Jiang, Po Yee Mak, Hong Mu, et al.
Pageof 72

Showing results (591-600 of 713) with videos related to

Sort By:
Pageof 72
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Blood|August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
Journal of Hematology & Oncology|January 5, 2019
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceKamal Chamoun, Hagop Kantarjian, Rami Atallah, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
American Journal of Hematology|January 5, 2017
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionNaveen Pemmaraju, Hagop Kantarjian, Jeffrey L Jorgensen, et al.
Blood|January 6, 2016
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsPreetesh Jain, Hagop Kantarjian, Keyur P Patel, et al.
Cancer|October 16, 2018
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential valueJuliana E Hidalgo-Lόpez, Rashmi Kanagal-Shamanna, Andrés E Quesada, et al.
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid LeukemiaXuejie Jiang, Po Yee Mak, Hong Mu, et al.
Pageof 72